Last reviewed · How we verify

NCT03462823: ACLROCS

Use of an Osteoconductive Scaffold in ACL-Reconstruction

Active, enrolled NA Last updated 6 August 2024
What this trial tests

NA trial testing Osteoconductive scaffold-hamstring tendon composite repair in ACL - Anterior Cruciate Ligament Rupture in 56 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
29 April 2017
Primary endpoint
29 January 2024
29 December 2025

Quick facts

Lead sponsorSandro Fucentese
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment56
Start date29 April 2017
Primary completion29 January 2024
Estimated completion29 December 2025
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Sandro Fucentese

Who can join

Adults 18 to 60, any sex, with ACL - Anterior Cruciate Ligament Rupture or ACL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary objective of the study is to evaluate efficacy of the surgical technique for ACL reconstruction using an osteoconductive scaffold, enlaced into the hamstring tendon autograft, compared to the traditional technique.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Osteoconductive Scaffold Placed at the Femoral Tunnel Aperture in Hamstring Tendon ACL Reconstruction: A Randomized Controlled Trial.
    Götschi T, Hodel S, Kühne N, Bachmann E, et al · · 2023 · cited 3× · PMID 37347015 · DOI 10.1177/23259671231174478

Verify or expand the search:

Other recruiting trials for ACL - Anterior Cruciate Ligament Rupture

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03462823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing